Volume 24 Number 11
15 June 2022

Home > Publications > Neuro-Oncology Reviews > Volume 24, Year 2022 > Number 11, 15 June

Mount CW, Gonzalez Castro LN.
Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors.
Antibodies (Basel). 2022 Apr 27;11(2):31. doi: 10.3390/antib11020031. PMID: 35645204. Review.

Wu J, Al-Zahrani A, Beylerli O, Sufianov R, Talybov R, Meshcheryakova S, Sufianova G, Gareev I, Sufianov A.
Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas.
Front Oncol. 2022 May 12;12:898537
. doi: 10.3389/fonc.2022.898537. PMID: 35646622. Review.

Mungur R, Zheng J, Wang B, Chen X, Zhan R, Tong Y.
Low-Intensity Focused Ultrasound Technique in Glioblastoma Multiforme Treatment.
Front Oncol. 2022 May 19;12:903059. doi: 10.3389/fonc.2022.903059. PMID: 35677164. Review.

Jang JK, Pyo J, Suh CH, Park HS, Chae YK, Kim KW.
Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis.
Front Oncol. 2022 May 26;12:851877
. doi: 10.3389/fonc.2022.851877. PMID: 35692797. Review and Meta-analysis.

Greuter L, Frank N, Guzman R, Soleman J.
The Clinical Applications of Liquid Biopsies in Pediatric Brain Tumors: A Systematic Literature Review.
Cancers (Basel). 2022 May 28;14(11):2683. doi: 10.3390/cancers14112683. PMID: 35681663. Review.

Melhem JM, Detsky J, Lim-Fat MJ, Perry JR.
Updates in IDH-Wildtype Glioblastoma.
Neurotherapeutics. 2022 May 31:1–19
. doi: 10.1007/s13311-022-01251-6. PMID: 35641844. Review.

Shah DS, Sanan A, Morell AA, Eichberg DG, Shah AH, Luther E, Lu VM, Elarjani T, Higgins DMO, Patel NV, Jagid JR, Ivan ME, Komotar RJ.
Traumatic brain injury and subsequent brain tumor development: a systematic review of the literature.
Neurosurg Rev. 2022 Jun 1
. doi: 10.1007/s10143-022-01819-y. PMID: 35641842. Review;

Shah HA, Mishra A, Gouzoulis MJ, Ben-Shalom N, D'Amico RS.
Analysis of factors leading to early termination in glioblastoma-related clinical trials.
J Neurooncol. 2022 Jun 1:1–7. doi: 10.1007/s11060-022-04039-y. PMID: 35648307. Review.

Dutra JAP, Luiz MT, Tavares Junior AG, Di Filippo LD, Carvalho SG, Chorilli M.
Temozolomide: an Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Curr Pharm Des. 2022 Jun 3
. doi: 10.2174/1381612828666220603152918. PMID: 35658888. Review;

Foss-Skiftesvik J, Stoltze UK.
Genetic predisposition to central nervous system tumors in children - what the neurosurgeon should know.
Acta Neurochir (Wien). 2022 Jun 3. doi: 10.1007/s00701-022-05258-y. PMID: 35660974. Review;

Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ.
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.
Br J Cancer. 2022 Jun 4. doi: 10.1038/s41416-022-01864-w. PMID: 35662275. Review;

Wyss J, Frank NA, Soleman J, Scheinemann K.
Novel Pharmacological Treatment Options in Pediatric Glioblastoma-A Systematic Review.
Cancers (Basel). 2022 Jun 6;14(11):2814. doi: 10.3390/cancers14112814. PMID: 35681794. Review.

Shoaf ML, Desjardins A.
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Neurotherapeutics. 2022 Jun 8. doi: 10.1007/s13311-022-01256-1. PMID: 35674873. Review;

Alamer OB, Jimenez AE, Azad TD, Bettegowda C, Mukherjee D.
H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
World Neurosurg. 2022 Jun 10:S1878-8750(22)00803-8
. doi: 10.1016/j.wneu.2022.06.020. PMID: 35697228. Review;

Lafay-Cousin L, Baroni L, Ramaswamy V, Bouffet E.
How do we approach the management of medulloblastoma in young children?
Pediatr Blood Cancer. 2022 Jun 10:e29838
. doi: 10.1002/pbc.29838. PMID: 35686728. Review;

Kreatsoulas D, Bolyard C, Wu BX, Cam H, Giglio P, Li Z.
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
J Hematol Oncol. 2022 Jun 11;15(1):80. doi: 10.1186/s13045-022-01298-0. PMID: 35690784. Review.

Motomura K, Ohka F, Aoki K, Saito R.
Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions.
Front Neurol. 2022 May 12;13:874826. doi: 10.3389/fneur.2022.874826. PMID: 35645972. Review.


Osborn AG, Louis DN, Poussaint TY, Linscott LL, Salzman KL.
The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know.
AJNR Am J Neuroradiol. 2022 Jun 16. doi: 10.3174/ajnr.A7462. PMID: 35710121. Review.